16 September 19
Crude spikes, Bellamy’s bid while Sims scraps guidance (BAL, SGM, BHP)
16 September 19
Crude spikes, Bellamy’s bid while Sims scraps guidance (BAL, SGM, BHP)
16 September 19
Subscribers questions (BHP, OZL, IIND, MSB, MGG, NCM, ASL, AWC, WSA, HLS)
15 September 19
Market Matters Weekend Report Sunday 15th September 2019
13 September 19
Tech continues to struggle
13 September 19
Does the Healthcare sector look poised to repeat 2018? (CSL, COH, RMD, ANN, PME)
12 September 19
Markets edge higher on better China – US trade rhetoric (FMG, SM1, ISX)
12 September 19
Income Report: What does the sell-off in bonds mean for traditional income stocks? (CSR, IGL, TLS, SKI, TCL)
12 September 19
Could Iran & Aramco become too much for the Oil sector? (WPL, BPT, STO)
11 September 19
Rinse and repeat (EVN)
10 September 19
OPEC Hope sends energy higher on a down day (SYR, WHC)
The ASX200 enjoyed another firm day to end February rallying another 18-points and as Led Zeppelin immortalised in both lyrics & movie “The song remains the same” – I just checked they released the concert film in 1976 showing, clearly I have taste beyond my years! The point I was attempting to make before getting carried away was the market opened, then rapidly slipped ~35-points before recovering from lunchtime and finally pushing to new daily highs after 3.30 pm – I’ve written a similar tale for many days in 2019. The ASX200 actually closed out February with its best monthly performance since 2016, investors are clearly now comfortable to buy shares again, especially as property is no longer regarded as a sure thing.
Under the hood we saw broad strength which was lead by the healthcare and banking sectors while profit taking looks to be creeping into some resource stocks, no major surprise after their recent stellar 3-month advance. It was nice to see our recent purchase Bingo Industries (ASXC: BIN) surge over 15% to be the top performer on the day but we won’t count our $$’s just yet, this is a fickle market where profits can vanish as quickly as they arrive i.e. remain open-minded and flexible.
The upside momentum of the local index continues to reduce but while our ideal short-term scenario is a pullback towards the psychological 6000 area no technical sell signals have materialised to-date.
MM remains in a patient “buy mode”, importantly we are not chasing the market in general at current levels.
Overnight US markets closed down -0.25% but the SPI futures are pointing to a slightly higher open locally.
Today we have looked at 5 names in the Healthcare sector which have caught our eye over recent weeks.
ASX200 March SPI Futures Chart
We have been discussing a few of the high flyers from the Software & Services Sector over recent weeks / months and they continue to evolve in an interesting manor although we are not yet considering pressing the “buy button”.
Afterpay Touch (ASX: APT) bounced over 4.5% yesterday after slipping 16% following its latest company update. If the stock follows its rhythm from 2018 its should now calm down for a few weeks with a likely downward bias towards $16.50-$17.
MM has interest in APT from a risk / reward perspective around 8% lower.
Afterpay Touch (ASX: APT) Chart
Its wonderful to see an Australian business excel in the overseas dominated Artificial Intelligence space (AI), and Appen is certainly doing that. The stock still feels relatively cheap considering its strong position in a new industry, its rare that we say a P/E of over 40x is not too concerning.
However following its recent explosive gains we feel prudence is to be patient, at least for now.
MM remains bullish APX looking for an opportune entry.
Appen Ltd (ASX: APX) Chart
No change with US markets, we still believe they have a strong risk to the downside with our target ~5% lower but we should a remember that tops, even short-term ones, generally take longer to evolve as opposed to bottoms which usually react like a tensioned spring board.
US Russell 2000 Chart
Yesterday President Trump demonstrated that he is not always the markets saviour as he walked away from negotiations with North Korea sending the South Korean KOSPI down close to 2%.
Expectations for Donald Trump’s second summit with Kim Jong Un were mixed but the market was taken by surprise by its abrupt end. The U.S. president said he walked out because the North Korean leader’s offer to dismantle the nation’s main nuclear facility at Yongbyon “wasn’t enough.” I actually thought the response by Trump and his associated explanation showed a rare moment of composure.
The Korean KOSPI Index Chart
No change with European indices who have reached major resistance and our target area following their ~12% bounce, we are now neutral to bearish from a simple risk / reward basis.
This reaffirms our believe that patience is likely to be rewarded with buying of the market in general – clearly not necessarily on a stock by stock basis.
German DAX Index Chart
Has the Healthcare Sector regained its “Mojo”?
Over the last 5 trading days stocks in the Healthcare Sector have garnered a clear “bid tone” with a few solid performances e.g. Ramsay Healthcare (ASX: RHC) +8.8%, ResMed (ASX: RMD) +3.6%, Sigma Healthcare (ASX: SIG) +7% and Nanosonics (ASX: NAN) +15%. This is arguably similar to what we have seen with other recently beaten down stocks across the index as investors search for relatively cheap exposure to a market that keeps climbing a wall of worry e.g. previous market favourites CSL (ASX: CSL) and Cochlear (ASX: COH) remain 16.7% and 23% respectively below their 2018 highs.
Today I have looked at 5 stocks in the sector to see if we can find any potential opportunities for the weeks ahead.
1 Ramsay Healthcare (ASX: RHC) $64.78
RHC has broken out to the upside with gusto following the release of their half year results which were solid, however importantly to us it’s the first time in a while we heard them talk about improvement in the UK and France. From an earnings perspective, profit came in a tad above expectations and guidance was more or less in line with current market expectations, however it was the commentary around volume growth in the UK and better pricing outcomes in France that underpinned the days buying.
RHC could certainly be considered a “dog” if we consider the last few years with the stocks still well over 20% below its 2016 high – remember the “dogs” have been a hot area of late. RHC is now trading on an Est P/E for 2019 of 21.3x which is low for a quality global healthcare company. Over the past 5 years, RHC’s average P/E has been 24.4x, the more recent discount a result of concerns about their big overseas expansion, and yesterday’s result goes so way of dispelling those concerns.
While they guided for profit growth of ‘up to 2%’ for FY19, RHC has been putting the foundations in for a ‘stronger for longer’ growth profile, and from 2020, they should be growing profits by around 10%
RHC Historical P/E
At this stage we are inclined to be observers short-term to see how the result is digested over the coming days / weeks with ideal entry a few $$ lower.
We are interested in RHC moving forward.
Ramsay Healthcare (ASX: RHC) Chart
2 Fisher & Paykel (ASX: FPH) $14.07
Last month FPH settled an annoying patent dispute with rival ResMed (ASX: RMD) and the board used the opportunity to announce that the settlement will not have a meaningful impact on its NPAT guidance for the 2019 financial year.
This respiratory care business has an excellent medium-term track record of growth which can be seen from the share price gains below. Similar to ResMed (ASX: RMD) its market opportunities are growing as countries like China and India mature economically. Following the recent price appreciation the stock is no longer in the cheap corner but we are still bullish with an eventual target ~10% higher.
We like FPH at present but feel our exposure to the area through ResMed is sufficient.
Fisher & Paykel (ASX: FPH) Chart
3 Healius Ltd (ASX: HLS) $2.78
In January Healius (the old Primary Healthcare) rallied following a conditional takeover offer at $3.25 per share from Jangho Group Hong Kong Limited who already own over 15% of the business.
Clearly the stock price implies that a deal completion is unlikely but as we saw with Healthscope (ASX: HSO) these things often have more than one chapter.
The hurdles to the current deal include due diligence and then often onerous Australian regulatory approvals (including the Foreign Investment Review Board) – perhaps BGH-Australian Super will have interest as there war chest looks for targets.
From a risk / reward perspective we like HLS at current levels.
Healius Ltd (ASX: HLS) Chart
4 Sonic Healthcare (ASX: SHL) $24.12
Interestingly SHL is down almost 2% over the last 5-days which ties in with our technically bearish view of the stock.
The medical diagnostics business released solid first half results last month and upgraded guidance but we are always wary a stock that cannot rally on good news. The stocks trading at fair value leading us to see better opportunities elsewhere within the sector.
MM has no interest in SHL at current levels.
Sonic Healthcare (ASX: SHL) Chart
5 Nanosonics (ASX: NAN) $4.15
The biotech business which specialises in the development /commercialisation of infection control has enjoyed a stellar 2019 after announcing first half revenue up over 35% and an operating profit after tax of $11m.
The business is well positioned moving forward following a renegotiated distribution deal in the US and a new earnings stream in the next few years from replacement/upgrade opportunities for their Trophon2 device. While earnings here are not the driver – growth is - maintaining current growth rates may- be challenging.
NAN is technically bullish while it holds above $3.60 but risk / reward opportunities are hard to identify.
MM is neutral / bullish at current levels.
Nanosonics (ASX: NAN) Chart
We own Resmed in the Platinum Portfolio and remain comfortable with the holding for now
Of the 5 stocks looked at today we like Healius (ASX: HLS) as a takeover play and Ramsay Healthcare (ASX: RHC) a few dollars lower.
Overnight Market Matters Wrap
· The US continued its descent overnight, ending its session lower however ending the month of February at a high, with the S&P 500 up 2.97% and the Dow up 3.67%.
· US GDP came in at 2.6% vs analyst’s expectations of 2.2%. Meanwhile, Fed officials argue that they can be patient given benign inflation and a weak world growth outlook, led by China. Caixin China PMI manufacturing data will be released at 12.45pm today, where analysts expect a reading of 48.5.
· Base metals were mixed, while iron ore rose. Gold fell to $US1313.13/oz. and crude crude oil continued to climb.
· The March SPI Futures is indicating the ASX 200 to open with little change this morning, around the 6170 level.
Have a great day!
James & the Market Matters Team
Market Matters may hold stocks mentioned in this report. Subscribers can view a full list of holdings on the website by clicking here. Positions are updated each Friday, or after the session when positions are traded.
All figures contained from sources believed to be accurate. Market Matters does not make any representation of warranty as to the accuracy of the figures and disclaims any liability resulting from any inaccuracy. Prices as at 01/03/2019
Reports and other documents published on this website and email (‘Reports’) are authored by Market Matters and the reports represent the views of Market Matters. The MarketMatters Report is based on technical analysis of companies, commodities and the market in general. Technical analysis focuses on interpreting charts and other data to determine what the market sentiment about a particular financial product is, or will be. Unlike fundamental analysis, it does not involve a detailed review of the company’s financial position.
The Reports contain general, as opposed to personal, advice. That means they are prepared for multiple distributions without consideration of your investment objectives, financial situation and needs (‘Personal Circumstances’). Accordingly, any advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not any advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of a financial advisor. Market Matters or its author(s) accepts no responsibility for any losses or damages resulting from decisions made from or because of information within this publication. Investing and trading in financial products are always risky, so you should do your own research before buying or selling a financial product.
The Reports are published by Market Matters in good faith based on the facts known to it at the time of their preparation and do not purport to contain all relevant information with respect to the financial products to which they relate. Although the Reports are based on information obtained from sources believed to be reliable, Market Matters does not make any representation or warranty that they are accurate, complete or up to date and Market Matters accepts no obligation to correct or update the information or opinions in the Reports. Market Matters may publish content sourced from external content providers.
If you rely on a Report, you do so at your own risk. Past performance is not an indication of future performance. Any projections are estimates only and may not be realised in the future. Except to the extent that liability under any law cannot be excluded, Market Matters disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.
Financial Services Guide
Date prepared: Wednesday, 22 November 2017
Last update: Friday, 23rd April 2019
About this Financial Services Guide (FSG)
This FSG provides you with key information about a range of subscription services offered by:
Marketmatters Pty Ltd (Market Matters) Australian Financial Services Licence No. 488798 ABN (20 137 462 536)
Level 29, Chifley Tower, 2 Chifley Square Sydney 2000
T: 1300 301 868
E: [email protected]
In this FSG, “we”, us” and “our” refer to Market Matters.
Market Matters holds Australian Financial Services Licence No. 488798 (AFSL) and is responsible for any financial services that we provide to you.
This AFSL was issued on 8th September 2016.
The purpose of this FSG is to provide you with information about:
Market Matters operates a website, www.marketmatters.com.au (Website), where customers may, for the payment of a subscription fee, access certain financial information and general advice. In particular, the Website provides:
This FSG relates only to the Website Services.
What financial services we can offer in connection with the Website Services
As holder of AFSL number 488798, in connection with the Website Services we are authorised to provide general financial product advice to both retail and wholesale clients in relation to the following financial products:
The Website Services are comprised of general advice only. That is, none of the advice given on the Website or by provision of the Website Services takes into account any of your objectives, financial situation or needs (Your Personal Circumstances). Before acting on any of the information, advice or Website Services, you must consider the appropriateness of this information in light of Your Personal Circumstances and, if necessary, consult a financial adviser before making any investment decision.
If you are seeking to acquire a specific financial product or security, you should obtain a copy of and consider the Product Disclosure Statement or Prospectus for that product before making any investment decision.
The Website does not provide a trading platform or access to a trading platform. There is no ability to purchase or sell financial products through the Website.
How do I access these services?
You can access these services by going to www.marketmatters.com.au and following the prompts and steps required to sign up for membership. Please read all terms and conditions carefully.
Fees and benefits payable to us and our associates
The Website is a subscription-based service. A yearly fixed subscription fee is payable to Market Matters when you subscribe to the Website which will vary depending on the type of subscription for which you subscribe. At the date of this FSG, the yearly subscription fees are as follows:
Platinum: $1,238 for 12 months
Platinum: $1,993 for 24 months
Subscription fees vary from time to time and are provided on the Website.
The Website does not currently feature third party advertising. Market Matters reserve the right to advertise at a future time for which they may receive remuneration. Any such advertising will be independent of any other content on the Website.
All representatives of Market Matters (Market Matters Staff) receive a salary paid by Market Matters. Market Matters Staff may also receive performance-based bonuses which are based on profitability, the number of subscribers and subscription renewal rates.
How do we manage potential conflicts of interest?
Market Matters have implemented policies and procedures to mitigate the risk of conflicts of interest. These include:
Market Matters Staff and Contributors are encouraged to express independent views and opinions on the topics they write about. This is established through ongoing training, external audits and our conflict of interest and staff trading policies. Market Matters Staff are required to serve the best interests of the subscribers, without consideration of any commercial or personal interests.
How is my personal information dealt with?
If you have a complaint about our services, you should take the following steps:
Contact us and discuss the complaint directly. If you do not feel comfortable discussing the complaint with us or your complaint is not satisfactorily resolved within 2 business days, please telephone Market Matters, on 1300 301 868 and ask to speak with the Complaints Officer. We suggest you put your complaint in writing at this time so that the issues are fully documented and understood by the parties. Your complaint should be addressed to:
The Complaints Officer
Level 29, Chifley Tower,
2 Chifley Square Sydney NSW 2000
Market Matters will review your complaint within 45 days and attempt resolution. If you are still not satisfied with the outcome, you may take your complaint to an external dispute resolution scheme. Market Matters is a member of the scheme operated by the Financial Ombudsman Service. You should write to:Australian Financial Complaints Authority Limited (AFCA)
You may also wish to consult ASIC in relation to your complaint. ASIC’s website contains information on complaining about companies and people and describes the types of complaints handled by ASIC. You can contact ASIC on its free call infoline:
Tel: 1300 300 630 or email [email protected]
We maintain professional indemnity insurance to cover our employees and Authorised Representatives (including us) for the financial services they provide, having regard to the following:
If you require further information about these compensation arrangements please contact us.
Terms and Conditions
This website, www.marketmatters.com.au, is published by Marketmatters Pty Limited (ABN 20 137 462 536) ('Market Matters', 'MM', 'us', 'we', 'our') Australian Financial Services Licence 488798
Financial Services Guide
Market Matters Financial Services Guide (FSG) is located here, and contains important information about the financial services provided by Market Matters. You must read our FSG and consider it in the context of your Personal Circumstances before acting on any advice. By accepting the terms and conditions you are acknowledging that you have read the FSG.
Provision of the Reports
Reports and other documents published on the Market Matter’s website (‘Reports’) are authored by Market Matters. The Reports represent the views of Market Matters based on technical analysis of companies, commodities and the market in general. Technical analysis focuses on interpreting charts and other data to determine what the market sentiment about a particular financial product is, or will be. Unlike fundamental analysis, it does not involve a detailed review of the company’s financial position.
The Reports contain general, as opposed to personal advice. That means they are prepared for multiple distribution without consideration of your investment objectives, financial situation and needs (‘Personal Circumstances’). Accordingly, any advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not any advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of a financial advisor.
The Reports are published by Market Matters in good faith based on the facts known to it at the time of their preparation and do not purport to contain all relevant information with respect to the financial products to which they relate. Although the Reports are based on information obtained from sources believed to be reliable, Market Matters does not make any representation or warranty that they are accurate, complete or up to date and Market Matters accepts no obligation to correct or update the information or opinions in the Reports.
If you rely on a Report, you do so at your own risk. Any projections are estimates only and may not be realised in the future. Except to the extent that liability under any law cannot be excluded, Market Matters disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.
Past performance is not a reliable indicator of future results. Brokerage costs have not been included in the calculation of performance. As financial products rise and fall in value, returns may be negative. Performance figures are not intended to be a forecast. Market Matters does not guarantee the performance of or returns on any investment.
Employees and/or associates of Market Matters may hold one or more of the stocks reviewed on this website.
Subscriptions and Subscription Prices
To access premium content available on the Market Matters website you may initially subscribe through the complimentary trial which provides you full access to all services for the trial period. You are limited to two trials after which you must subscribe to one or more membership categories available on the website or direct with Market Matters before you can trial the service again, three months after the expiry of your second trial.
To subscribe to Market Matters services and access to the website you may go to the Memberships page of the website, provide the information marked as ‘Mandatory’ and select the payment option for the price quoted (at the time of your transaction) or contact the team directly at Market Matters by phone or email. You will then receive a verification email from Market Matters indicating that your subscription and payment have been accepted and you will be able to access the premium content.
Prices published on the Market Matters website are quoted in Australian Dollars (AUD) and are inclusive of GST and/or all other duties and taxes. Market Matters has used reasonable endeavours to ensure that prices for subscription to its services are published accurately on the website but these prices are subject to change and Market Matters reserves the right to change these prices and will notify you of any increase by email (with the price increase to apply from the time the next payment is due).
Marketmatters Pty Ltd (ABN 20 137 462 536) will issue a tax invoice to paying subscribers in relation to any supply that is subject to GST in accordance with A New Tax System (Goods and Services Tax) Act 1999.
Any member is entitled to cancel their membership at any time. In the event a member does wish to cancel their subscription, cancellations must be notified in writing to:
Level 29, Chifley Tower, 2 Chifley Square, Sydney NSW 2000
or by email to: [email protected]
All cancellations of month-by-month subscriptions will be cancelled and not billed again the following month.
All cancellations within 14 days we be entitled to a full refund. Any introductory gifts, such as, but not limited to; iPads, Fitbit watches, Apple watches, Google Homes, must be returned in their original condition before a refund will be made.
All cancellations made after 14 days of subscription commencement will not be entitled to a refund unless in the event of extenuating circumstances, at the sole discretion of Market Matters.
Subscriptions will automatically renew on the expiry date of current subscription. In these instances the subscription will be renewed at the current rate published on the Market Matters web site, using the same credit card that paid for the initial subscription, unless otherwise requested by the subscriber. A subscriber who wishes to cancel after being renewed in this way will have a “14 day cooling off period” in which they can request to discontinue and will receive a full refund for the renewal payment, this can be done in writing to:
Level 29, Chifley Tower, 2 Chifley Square Sydney 2000
or by email to: [email protected]
Market Matters has not reviewed any of the websites which link to this website or to which this website links. Market Matters is not responsible for the content of any other website or pages linked to or linking to its website. Following links to any other websites or pages shall be at the user’s own risk.
Copyright © 2018 Marketmatters Pty Ltd (ABN 20 137 462 536). No part of this website, or its content, may be reproduced in any form without the prior consent of Market Matters.
This Agreement is governed by and is to be construed in accordance with the laws of New South Wales, Australia. You agree to the non-exclusive jurisdiction of the courts of New South Wales, Australia in respect of any proceedings concerning this Agreement. This website is not available to US and/or EU persons and by accepting these terms you confirm that you are not a US and/or EU person.